Trevi Therapeutics to Report Q3 2021 Financial Results and Provide a Corporate Update on Wednesday, November 10, 2021

Rhea-AI Summary

Trevi Therapeutics (Nasdaq: TRVI) will host a conference call and live audio webcast on November 10 at 4:30 p.m. ET to discuss its Q3 2021 financial results and provide a corporate update. Trevi focuses on developing Haduvio™ (nalbuphine ER) for serious neurological conditions, conducting Phase 2b/3 trials for chronic pruritus and Phase 2 trials for chronic cough in idiopathic pulmonary fibrosis patients. Haduvio has received Fast Track designation by the FDA for prurigo nodularis, although its safety and efficacy are yet to be evaluated.

NEW HAVEN, Conn., Nov. 3, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of an investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management will host a conference call and live audio webcast on Wednesday, November 10 at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the third quarter ended September 30, 2021.

Trevi Therapeutics hosting conference call on Q3 2021 financial results and company update on November 10th

To participate in the live conference call by phone, please dial (888) 317-6003 (domestic) or (412) 317-6061 (international) and provide access code 6938277. A live audio webcast will be accessible from the 'Investors & News' section on the Company's website at www.trevitherapeutics.com. An archived replay of the webcast will also be available for 30 days on the Company's website following the event.  

About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio to treat serious neurologically mediated conditions. Trevi is conducting a Phase 2b/3 clinical trial of Haduvio for the treatment of chronic pruritus associated with prurigo nodularis (PN) and a Phase 2 trial for chronic cough in patients with idiopathic pulmonary fibrosis (IPF). Trevi is also developing Haduvio for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease. These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems.

Founded in 2011, Trevi Therapeutics is headquartered in New Haven, CT.

About Haduvio
Haduvio, an investigational therapy, is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed ĸ-opioid receptor agonist and µ-opioid receptor antagonist that has been approved and marketed as an injectable for pain indications for more than 20 years in the United States and Europe. The ĸ- and µ-opioid receptors are known to be critical mediators of itch, cough and certain movement disorders. Nalbuphine's mechanism of action may also mitigate the risk of abuse associated with µ-opioid agonists because it antagonizes, or blocks, µ-opioid receptors. Parenteral nalbuphine is not currently classified as a controlled substance by the DEA in the United States and by regulatory authorities in most of Europe. Trevi intends to propose Haduvio as the trade name for nalbuphine ER. Haduvio is an investigational therapy that has been granted Fast Track designation by the FDA for the proposed indication of reduction of moderate to severe pruritus in patients with prurigo nodularis. Its safety and efficacy have not been evaluated by any regulatory authority.

Investor Contact
Katie McManus
Trevi Therapeutics, Inc.
203-304-2499
k.mcmanus@trevitherapeutics.com 

Media Contact 
Rosalia Scampoli
914-815-1465
rscampoli@marketcompr.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-to-report-q3-2021-financial-results-and-provide-a-corporate-update-on-wednesday-november-10-2021-301415752.html

SOURCE Trevi Therapeutics, Inc.

FAQ

When will Trevi Therapeutics report Q3 2021 financial results?

Trevi Therapeutics will report Q3 2021 financial results on November 10, 2021.

What is Haduvio and its significance for Trevi Therapeutics?

Haduvio is an investigational therapy by Trevi Therapeutics, focused on treating serious neurologically mediated conditions, currently undergoing clinical trials.

What trials is Trevi Therapeutics conducting for Haduvio?

Trevi is conducting a Phase 2b/3 trial for chronic pruritus and a Phase 2 trial for chronic cough in patients with idiopathic pulmonary fibrosis.

What designation has Haduvio received from the FDA?

Haduvio has received Fast Track designation from the FDA for treating moderate to severe pruritus in patients with prurigo nodularis.